MedPath

European Commission Approves Pfizer's Hympavzi for Hemophilia A and B

• The European Commission has approved Pfizer's Hympavzi for routine prevention of bleeding episodes in hemophilia A and B patients aged 12 and older. • Hympavzi is the first once-weekly subcutaneous treatment in the EU for severe hemophilia B, offering a new administration route. • The approval extends to patients with severe hemophilia A, providing the first pre-filled pen or syringe option in the EU. • The U.S. Food and Drug Administration (FDA) had previously approved Hympavzi in October, marking its global expansion.

Pfizer has received approval from the European Commission for its Hympavzi treatment, indicated for the routine prevention of bleeding episodes in patients 12 years and older with severe hemophilia A or B without inhibitors. This decision marks a significant advancement in hemophilia care within the European Union.
Hympavzi stands out as the first once-weekly subcutaneous treatment available in the EU for individuals with severe hemophilia B. Furthermore, it is the first treatment option, for both severe hemophilia A and B, that can be administered via a pre-filled pen or syringe, offering a more convenient and potentially less intimidating administration method for patients.
The approval by the European Commission follows the U.S. Food and Drug Administration's (FDA) approval of Hympavzi in October, highlighting the growing recognition of its clinical value. This approval allows for the broader use of Hympavzi, potentially improving the quality of life for numerous patients with hemophilia across Europe.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

European Commission Approves Pfizer's Hympavzi for Haemophilia A and B

The European Commission (EC) has approved Pfizer's Hympavzi (marstacimab) for routine prophylaxis of bleeding episodes in haemophilia A and B patients.
Hympavzi is the first anti-tissue factor pathway inhibitor approved in the EU for haemophilia A or B, administered via a pre-filled, auto-injector pen.

EU Approves Pfizer's Hympavzi for Hemophilia A and B

The European Commission has granted marketing authorization for Pfizer's Hympavzi (marstacimab) for hemophilia A and B patients aged 12 and older.
Hympavzi is a once-weekly prophylactic treatment to reduce bleeding episodes in patients without inhibitors to Factor VIII (FVIII) or Factor IX (FIX).

Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU - MSN

EU Approves Pfizer's Hympavzi for Severe Hemophilia A and B

The European Commission has granted marketing authorization for Hympavzi, a new treatment developed by Pfizer.
Hympavzi is indicated for severe hemophilia A or B in both adult and adolescent patients without inhibitors.

European Commission Approves Pfizer's HYMPAVZI for Hemophilia A and B

The European Commission has granted marketing authorization to Pfizer's HYMPAVZI (marstacimab) for treating hemophilia A and B based on Phase 3 trial results.
HYMPAVZI is the first once-weekly, subcutaneous treatment in the EU for severe hemophilia B and can be administered via a pre-filled, auto-injector pen.

EU Approves Pfizer's Hympavzi as First Weekly Subcutaneous Treatment for Severe Hemophilia B

The European Commission has approved Pfizer's Hympavzi, a once-weekly subcutaneous treatment, for severe hemophilia B in adults and adolescents without inhibitors.
Hympavzi is the first anti-TFPI antibody approved in Europe for hemophilia A or B without inhibitors, offering convenient at-home administration via autoinjector.

FDA Approves Hympavzi (marstacimab-hncq) as Novel Treatment for Hemophilia A and B

The FDA has approved Hympavzi (marstacimab-hncq), a novel monoclonal antibody, for hemophilia A and B in patients 12 years and older.
Hympavzi offers a new mechanism by reducing tissue factor pathway inhibitor, enhancing thrombin production to facilitate blood clotting.

FDA Approves Pfizer's Hympavzi (marstacimab-hncq) for Hemophilia A and B

The FDA has approved Hympavzi (marstacimab-hncq) for routine prophylaxis to reduce bleeding episodes in hemophilia A and B patients without inhibitors, aged 12 and older.
Hympavzi is the first anti-TFPI therapy approved in the U.S. for hemophilia A or B, offering a once-weekly subcutaneous administration via a pre-filled auto-injector pen.

Hympavzi (Marstacimab) Approved in the US for Hemophilia A and B Prophylaxis

Hympavzi (marstacimab-hncq) has been approved in the US for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A or B without inhibitors.
As a once-weekly subcutaneous injection, Hympavzi offers a convenient alternative to frequent intravenous infusions of factor VIII or IX replacement therapies.

FDA Approves Pfizer's Hympavzi for Hemophilia A and B

The FDA has approved Hympavzi (marstacimab-hncq), a once-weekly subcutaneous injection, for hemophilia A and B to prevent or reduce bleeding episodes.
Hympavzi is the first anti-tissue factor pathway inhibitor (anti-TFPI) approved in the U.S. for hemophilia A or B, offering a new mechanism of action.

Reference News

[1]
Pfizer Gets European Approval of Hympavzi Hemophilia Drug - Morningstar
morningstar.com · Nov 20, 2024

Pfizer wins European Commission approval for Hympavzi, a once-weekly subcutaneous treatment for severe hemophilia A or B...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy